Health Professional Radio - Podcast

John Temperato, CEO of RDD Pharma and what will be 9 Meters Biotechnology, discusses GI diseases, current treatments, why there are still unmet needs for diseases like celiac and others, and what's on the horizon. Through the RDD/Innovate merger, 9 Meters will have larazotide, the first-ever drug candidate to enter Phase 3 registration trials for celiac disease.